(Date:12/16/2009)... /PRNewswire/ -- Capitalizing on the continued ... an active venture capital market, leaders from BioCrossroads, ... Fund, Indiana University, Purdue University, the University of ... Suisse today announced the establishment of the INext ... funds. ,, Organized through BioCrossroads, Indiana,s initiative to ...
(Date:12/16/2009)... culture supplement? InVitria has what scientists have been asking for! ... improves the growth and productivity of CHO cells. Developed for ... animal free, well defined and consistent recombinant CHO supplement. ... ... 16, 2009 -- Scientists working with CHO cells can now ...
(Date:12/15/2009)... (JBEI), one of three Department of Energy (DOE) bio-energy ... to protect its valuable intellectual property. , ... ... 15, 2009 -- Surety, LLC , the leading ... announced that the Joint BioEnergy Institute (JBEI), one of ...
(Date:12/15/2009)... Va., Dec. 15 AstraZeneca (NYSE: ... of Virginia (UVa) in Charlottesville, today announced ... research collaboration to enhance development of new ... with a secondary focus on peripheral vascular ... ) ,, The collaborative preclinical research projects ...
Breaking Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3... 25 NuVasive, Inc. (Nasdaq:,NUVA), a medical device company ... the spine, announced today,details relating to its fourth quarter ... on Tuesday, February 19, 2008, after,the close of the ... Tuesday, February 19, 2008 at,5:30 p.m. ET / 2:30 ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today that ... of a second generation oral niacin receptor agonist,under a ... of atherosclerosis and other disorders. The initiation of this,trial ... very pleased with the progress of this collaboration,investigating the ...
... 24 ,Exelixis, Inc. (Nasdaq: EXEL ) announced today ... of Exelixis, will present at,the 2008 Wachovia Healthcare Conference ... January 31, 2008., The presentation will be webcast ... Investors on the Exelixis website at, http://www.exelixis.com ., ...
Other Biology Technology:NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 2NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 3Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 3Vesicular Glutamate Transporter 2 [VGLUT2]...
...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Anti-HumanLactoferrin...
Biology Products:Biology NavigationMedical Navigation